newsfilter
← Latest News
GlobeNewswire·

Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results

-- Topline data in ANG-3777 Phase 3 study now expected to be announced in early Q4 rather than at year end -- Phase 1 data demonstrated ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which ac